Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs BV NSCLC 001 (Primary) ; Cyclophosphamide
- Indications Carcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bioven
- 09 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 09 Jul 2019 Planned End Date changed from 1 May 2019 to 1 Sep 2019.
- 09 Jul 2019 Planned primary completion date changed from 1 May 2019 to 1 Sep 2019.